3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE, CA
Market cap: $94.1M (2/12/2026)
Price: $2.82
Reports Encouraging Patient Survival Observations in Ovarian Cancer CAR-T Trial; Achieves Regulatory Approval Enabling Major Dose Escalation
Announces Positive Phase 1 Data for Investigational Breast Cancer Vaccine; Primary Endpoints Were Met and Immune Response Observed in 74% of Participants
Investor Presentation
.2
Expands Partnership with Cleveland Clinic to Develop Additional Cancer Vaccines
Positive New Data from Phase 1 Study of Breast Cancer Vaccine
Positive Data for Phase 1 Study of Breast Cancer Vaccine
FY 2025
Q3
Q2
FY 2024
Q1
FY 2023
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Amended Schedule 13D - Ownership Report
Correspondence
Submission Upload
Delisting Amendment
Free Writing Prospectus